Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Power3 Medical Announces Better Than Expected Results For Early Stage Diagnosis Capability Of The NuroPro(R) PD Test For Parkinson's Disease
Power3 Medical Products, Inc. (OTCBB: PWRM), announced that results for the early stage diagnosis from clinical validation trials of the NuroPro® PD test for Parkinson"s disease are better than expected. The NuroPro PD test was developed to help clinicians distinguish patients with Parkinson"s disease from "normal" individuals and patients with other neurological disorders. The NuroPro PD test, developed by Power3, utilizes a panel of blood serum protein biomarkers evaluated by biostatistical analysis to predict the probability that a patient has Parkinson"s disease. The test is intended to solve a critical challenge facing physicians, clinicians, and patients for a quick, early stage and accurate diagnosis of the debilitating disease known as Parkinson"s.
generic viagra online
Nursing Workforce Solutions For 21st Century Health Care: How Do We Get There?
At a June 12 forum cosponsored by Health
News of the day
Court Of Appeal To Re-Evaluate NICE Osteoporosis Decision, UK
Servier Laboratories Limited has been granted permission by the Court of Appeal to challenge a High Court decision made at a Judicial Review in February this year, in which Servier was previously successful in its claim that the National Institute for Health and Clinical Excellence (NICE) had unlawfully failed to provide the economic model underlying its Guidance for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. 1,2
Sexual Health

FDA Issues Advertising Guidelines On Product Risk Information

FDA on Tuesday posted on its Web site advertising guidelines for drugmakers and medical device manufacturers, offering suggestions on how to present risk information to health care professionals and consumers, the Wall Street Journal reports. Agency officials said the industry had asked for guidance on how to comply with its rules, which require a balanced presentation of a product"s risk and effectiveness. Exclusion or minimization of risk information is the most commonly cited violation each year in FDA-issued warnings or enforcement letters. The new guidelines include detailed information on how aspects such as font, types of contrast and white space in print materials can appropriately present risk information. According to the Journal, the 24-page document is not binding. FDA will accept public comments for 90 days prior to issuing final guidelines (Corbett Dooren, Wall Street Journal, 5/27). Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009